Feb 17, 2012 – Animal Pharm Reports on NewMarket

February 17, 2012

London – In the current issue of Animal Pharm, Jamie Day reports on a new partnership which aims to introduce an innovative systemic drug delivery technology to the animal health market. The two partners, both from New Jersey in the US, claim that the platform obviates the need for needles while ensuring more of the active ingredient arrives at the target area.

NewMarket Pharmaceuticals of Princeton and Catalent Pharma Solutions, based in Somerset in the same state, have signed a global licensing agreement to develop and formulate a line of products for both food-producing and companion animals using Catalent’s Zydis fast dissolve oral tablet technology. The combination of Zydis and NewMarket’s Direct Systemic Introduction (DSI platform) will enable the partners to develop a portfolio of new animal health products that could provide “significant advantages over existing formulations currently used across a spectrum of indications.”

NewMarket said that it has five drugs under development that combine the Zydis and DSI technologies. These include non-steroidal anti-inflammatory drugs (NSAIDs), beta agonists, proton pump inhibitors and behavior modifiers for horses, dogs and cattle.

“These easy-to-use formulations provide a clear advantage over traditionally ingested dosage forms and show the potential to revolutionize the way we treat animals by providing for a simple, efficient, accurate method of treatment without the use of needles,” stated Mark Ridall, NewMarket CEO.

“Our studies have determined that rapidly dissolving tablets are absorbed directly into the animal’s system, bypassing gastric absorption and metabolism and providing a greater amount of drug to that animal more rapidly than conventional formulations,” added Dr. David Rock, who joined NewMarket as vice-president for research and development in 2010. His 30 year career in animal health included spells with Fort Dodge and Pfizer Animal Health. “These products offer livestock producers and pet parents products that are easy to use and will provide the correct amount of product per label instructions.”

The NewMarket business was established recently to modernise the drug delivery systems used to treat animals, it says. It aims to reformulate veterinary drugs with proven safety and efficacy profiles so that they can be administered in a faster, safer, easier and more accurate manner. This also has the potential to grow the market for these products. The company claims that drugs in a fast dissolving form for oral absorption make more active ingredient available for the therapeutic treatment than traditional formulations such as injectables, pills, pastes, granules and other delivery methods. The DSI formulation platform is claimed to “avoid the destructive activities that begin in the stomach and continue through the gastrointestinal tract”. Instead the “pre-gastric uptake of the drug avoids first-pass metabolic activities, resulting in greater availability of the drug for therapeutic activity”.

Catalent is a biopharmaceutical contract research organisation created in 2007 through the private equity acquisition of a division of Cardinal Health. It helps clients develop new products and bring them to market, as well as advising on the life cycle of existing products.

Previous post: